➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKesson
Express Scripts
Baxter
Medtronic

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,694,071

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,694,071
Title:Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
Abstract: Highly effective combinations of a compound of formula A (a PI3K.delta. selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K.delta. and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
Inventor(s): Weiss; Michael S. (New York, NY), Miskin; Hari P. (New York, NY), Sportelli; Peter (New York, NY), Vakkalanka; Swaroop K. V. S. (La Chaux de Fonds, CH)
Assignee: TG Therapeutics, Inc. (New York, NY) Rhizen Pharmaceuticals NA (CH) Laboratoire Francais du Fractionnement et des Biotechnologies (FR)
Application Number:14/440,139
Patent Claims:see list of patent claims

Details for Patent 9,694,071

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial TG Therapeutics, Inc. (New York, NY) Rhizen Pharmaceuticals NA (CH) Laboratoire Francais du Fractionnement et des Biotechnologies (FR) 2032-11-02 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial TG Therapeutics, Inc. (New York, NY) Rhizen Pharmaceuticals NA (CH) Laboratoire Francais du Fractionnement et des Biotechnologies (FR) 2032-11-02 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial TG Therapeutics, Inc. (New York, NY) Rhizen Pharmaceuticals NA (CH) Laboratoire Francais du Fractionnement et des Biotechnologies (FR) 2032-11-02 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial TG Therapeutics, Inc. (New York, NY) Rhizen Pharmaceuticals NA (CH) Laboratoire Francais du Fractionnement et des Biotechnologies (FR) 2032-11-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Medtronic
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.